Covalent structure, synthesis, and structure-function studies of mesentericin Y 105(37), a defensive peptide from gram-positive bacteria Leuconostoc mesenteroides
- PMID: 8662868
- DOI: 10.1074/jbc.271.24.14421
Covalent structure, synthesis, and structure-function studies of mesentericin Y 105(37), a defensive peptide from gram-positive bacteria Leuconostoc mesenteroides
Abstract
A 37-residue cationic antimicrobial peptide named mesentericin Y 105(37) was purified to homogeneity from cell-free culture supernatant of the Gram-positive bacterium Leuconostoc mesenteroides. The complete amino acid sequence of the peptide, KYYGNGVHCTKSGCSVNWGEAASAGIHRLANGGNGFW, has been established by automated Edman degradation, mass spectrometry, and solid phase synthesis. Mesentericin Y 105(37) contains a single intramolecular disulfide bond that forms a 6-membered ring within the molecule. Mesentericin Y 105(37) was synthesized by the solid phase method. The synthetic replicate was shown to be indistinguishable from the natural peptide with respect to electrophoretic and chromatographic properties, mass spectrometry analysis, automated amino acid sequence determination, and antimicrobial properties. At nanomolar concentrations, synthetic mesentericin Y 105(37) is active against Gram+ bacteria in the genera Lactobacillus and Carnobacterium. Most interestingly, the peptide is inhibitory to the growth of the food-borne pathogen Listeria. CD spectra of mesentericin Y 105(37) in low polarity medium, which mimic the lipophilicity of the membrane of target organisms, indicated 30-40% alpha-helical conformation, and predictions of secondary structure suggested that the peptide can be configured as an amphipathic helix spanning over residues 17-31. To reveal the molecular basis of the specificity of mesentericin Y 105(37) targetting and mode of action, NH2- or COOH-terminally truncated analogs together with point-substituted analogs were synthesized and evaluated for their ability to inhibit the growth of Listeria ivanovii. In sharp contrast with broad spectrum alpha-helical antimicrobial peptides from vertebrate animals, which can be shortened to 14-18 residues without deleterious effect on potency, molecular elements responsible for anti-Listeria activity of mesentericin Y 105(37) are to be traced at once to the NH2-terminal tripeptide KYY, the disulfide bridge, the putative alpha-helical domain 17-31, and the COOH-terminal tryptophan residue of the molecule. It is proposed that the amphipathic helical domain of the peptide interacts with lipid bilayers, leading subsequently to alteration of the membrane functions, whereas residues 1-14 form part of a recognition structure for a membrane-bound receptor, which may be critical for peptide targetting. Because mesentericin Y 105(37) is easy to synthesize at low cost, it may represent a useful and tractable tool as a starting point for the design of more potent analogs that may be of potential applicability in foods preservation.
Similar articles
-
Mutational analysis of mesentericin y105, an anti-Listeria bacteriocin, for determination of impact on bactericidal activity, in vitro secondary structure, and membrane interaction.Appl Environ Microbiol. 2004 Aug;70(8):4672-80. doi: 10.1128/AEM.70.8.4672-4680.2004. Appl Environ Microbiol. 2004. PMID: 15294801 Free PMC article.
-
Leuconostoc mesenteroides subsp. mesenteroides FR52 synthesizes two distinct bacteriocins.Lett Appl Microbiol. 1996 Aug;23(2):120-4. doi: 10.1111/j.1472-765x.1996.tb00045.x. Lett Appl Microbiol. 1996. PMID: 8987453
-
Characterization and purification of mesentericin Y105, an anti-Listeria bacteriocin from Leuconostoc mesenteroides.J Gen Microbiol. 1992 Dec;138(12):2725-31. doi: 10.1099/00221287-138-12-2725. J Gen Microbiol. 1992. PMID: 1487737
-
Bacteriocins produced by Leuconostoc species.J Dairy Sci. 1994 Sep;77(9):2718-24. doi: 10.3168/jds.S0022-0302(94)77214-3. J Dairy Sci. 1994. PMID: 7814741 Review.
-
Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by gram-positive bacteria.Curr Pharm Biotechnol. 2009 Jan;10(1):19-37. doi: 10.2174/138920109787048661. Curr Pharm Biotechnol. 2009. PMID: 19149588 Review.
Cited by
-
Identification, characterization, and recombinant expression of epidermicin NI01, a novel unmodified bacteriocin produced by Staphylococcus epidermidis that displays potent activity against Staphylococci.Antimicrob Agents Chemother. 2012 Mar;56(3):1539-47. doi: 10.1128/AAC.05397-11. Epub 2011 Dec 12. Antimicrob Agents Chemother. 2012. PMID: 22155816 Free PMC article.
-
Recent Progress in the Chemical Synthesis of Class II and S-Glycosylated Bacteriocins.Front Microbiol. 2018 May 23;9:1048. doi: 10.3389/fmicb.2018.01048. eCollection 2018. Front Microbiol. 2018. PMID: 29875754 Free PMC article. Review.
-
Determination of essential and variable residues in pediocin PA-1 by NNK scanning.Appl Environ Microbiol. 2006 Feb;72(2):1141-7. doi: 10.1128/AEM.72.2.1141-1147.2006. Appl Environ Microbiol. 2006. PMID: 16461660 Free PMC article.
-
Delineation of key amino acid side chains and peptide domains for antimicrobial properties of divercin V41, a pediocin-like bacteriocin secreted by Carnobacterium divergens V41.Appl Environ Microbiol. 1999 Jul;65(7):2895-900. doi: 10.1128/AEM.65.7.2895-2900.1999. Appl Environ Microbiol. 1999. PMID: 10388680 Free PMC article.
-
Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo.Biomolecules. 2018 Jan 19;8(1):4. doi: 10.3390/biom8010004. Biomolecules. 2018. PMID: 29351202 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical